- Home
- FTLF vs CRDF Comparison
FTLF vs CRDF Comparison
Compare FTLF & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTLF | CRDF |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.8M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FTLF | CRDF |
|---|---|---|
| Price | $17.68 | $2.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $23.00 | $10.63 |
| AVG Volume (30 Days) | 13.4K | ★ 741.7K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $70,561,000.00 | $501,000.00 |
| Revenue This Year | $34.34 | N/A |
| Revenue Next Year | $48.58 | N/A |
| P/E Ratio | $25.78 | ★ N/A |
| Revenue Growth | ★ 12.44 | N/A |
| 52 Week Low | $9.83 | $1.90 |
| 52 Week High | $20.98 | $5.64 |
Technical Indicators
Market Signals| Indicator | FTLF | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 42.90 |
| Support Level | $17.62 | $1.90 |
| Resistance Level | $19.23 | $2.37 |
| Average True Range (ATR) | 0.87 | 0.12 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 11.22 | 29.79 |
Price Performance
Historical ComparisonAbout FTLF FitLife Brands Inc.
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.